|
- Probiotic Markedly Reduces S. aureus Colonization in Phase 2 Trial
A promising approach to control Staphylococcus aureus bacterial colonization in people—using a probiotic instead of antibiotics—was safe and highly effective in a Phase 2 clinical trial The new study, reported in The Lancet Microbe, found that the probiotic Bacillus subtilis markedly reduced S aureus colonization in trial participants without harming the gut microbiota, which includes
- Antimicrobial Resistance Threats - National Institute of Allergy and . . .
Methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-resistant Staphylococcus aureus (VRSA) S aureus bacteria are a leading cause of healthcare-associated infections in the U S Some people carry the bacteria in their noses and it does not cause infection
- Otto. fm - National Institute of Allergy and Infectious Diseases (NIAID)
Although a relatively unspectacular, nonmotile coccus, Staphylococcus aureus is a dangerous pathogen and a major public health concern In addition to being a common food-poisoning agent, it can cause serious skin and soft tissue infections and life-threatening diseases Further-more, resistance to multiple antibiotics, most notably to penicillin and methicillin, is common in S aureus and
- Trial of Existing Antibiotic for Treating Staphylococcus aureus . . .
A clinical trial to test the antibiotic dalbavancin for safety and efficacy in treating complicated Staphylococcus aureus (S aureus) bacteremia has begun The trial will enroll 200 adults hospitalized with complicated S aureus infection at approximately 20 trial sites around the United States The trial is being sponsored by the National Institute of Allergy and Infectious Diseases (NIAID
- Antibacterial Resistance Leadership Group (ARLG)
Main Areas of Focus The renewed ARLG program is focused on three priorities: Infections caused by Gram-negative bacteria, such as Escherichia coli, Klebsiella pneumoniae, and other carbapenem-resistant Enterobacteriaceae (CRE) Infections caused by Gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci Diagnostic tests to optimize use of
- Medicinal Chemistry - Infectious Diseases
Pathogens A microorganism that causes disease is called a pathogen Can be bacteria, virus, protozoa, fungus Methicillin-resistant Staphylococcus aureus (MRSA) Human immunodeficiency virus (HIV) Giardia lamblia Candida albicans
- Synthetic Tetracyclines To Combat Bacterial Infections
TP-6076 has been advanced to clinical Phase I trials These compounds are being developed for numerous bacterial indications, including community-acquired bacterial pneumonia, MDR gram-negative bacteria, methicillin-resistant Staphylococcus aureus (MRSA), Bacillus anthracis, Fransicella tularensis, and Yersinia pestis
- Rapid Diagnostics to Combat Antimicrobial Resistance
NIAID has also provided support for other novel approaches to diagnostics, including using digital imaging to rapidly detect Methicillin-resistant Staphylococcus aureus (MRSA), as well as and using a technique known as surface-enhanced Raman spectroscopy as a diagnostic platform to detect bacteria and antibiotic susceptibility
|
|
|